Indivior Pharmaceuticals Reports Results for Period Ended June 30, 2026

What Happened

• On August 3, 2026, Indivior Pharmaceuticals, Inc. announced its financial results for the period ended June 30, 2026 via a press release furnished as Exhibit 99.1 to a Form 8‑K (Item 2.02). The company also posted presentation materials on its website (furnished as Exhibit 99.2; Item 7.01). The filing (Accession No. 0001193125-26-329520) notes the release and slides but does not include additional narrative in the 8‑K itself.

Key Details

• Date of filing: August 3, 2026 (Form 8‑K).
• Reporting period: Financial results for the period ended June 30, 2026.
• Materials provided: Press release (Exhibit 99.1) and presentation slides (Exhibit 99.2) posted to the company website.
• Regulation FD disclosure: Presentation materials were posted publicly under Item 7.01.

Why It Matters

• The 8‑K makes Indivior’s most recent quarterly financial results and investor presentation publicly available; investors should review the press release and slides for revenue, earnings, cash position, and any commentary on guidance or business developments. Because the filing is a furnishing of materials (not a full earnings transcript), investors should read the exhibits on Indivior’s website or the SEC filings for the detailed figures and management commentary.